Skip to content
Screener

Prime Medicine PRME Shares (Diluted)

Shares (Diluted) at other companies

Eli Lilly logo
Eli LillyLLY
893.7M-0.7%
Vertex Pharmaceuticals logo
Vertex PharmaceuticalsVRTX
255.2M-1.4%
Intellia Therapeutics logo
Intellia TherapeuticsNTLA
133.5M+28.7%
CRISPR Therapeutics logo
CRISPR TherapeuticsCRSP
96.1M+11.8%
Beam Therapeutics logo
Beam TherapeuticsBEAM
103.3M+17.4%
Regenxbio logo
RegenxbioRGNX
53M+3.0%

Other financials

Income statement

See full
Revenue$838.0K-61.6%
Operating income-$43.3M+18.9%
Net income-$42.1M+19.9%
EPS (diluted)-$0.24+41.5%

Balance sheet

See full
Cash & equivalents$61.1M-9.4%
Total debt$112.5M-6.1%
Total equity$39.8M-34.6%
Total assets$249.0M-10.7%

Cash flow

See full
Operating cash flow-$41.0M+0.9%
CapEx$46.0K-97.1%
Free cash flow-$41.1M+4.4%

Valuation

See full
Market cap$558.64M-10.7%
Enterprise value$609.98M-10.0%

Profitability

See full
Operating margin-4,498.1%-1,134pp
Net margin-4,342.4%-1,099pp
FCF margin-3,607.4%

Returns & leverage

See full
Return on equity-373.3%-1,281pp
Debt / equity2.8×+0.9×
Current ratio3.1×-0.5×

Where this comes from

Reported directly by Prime Medicine in its filing.

Tagged under the XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding.

The source filing: Prime Medicine’s 10-Q, filed August 6, 2026.

Filed
Aug 6, 2026, 8:03 AM EDT
Fiscal quarter
Q2 FY2026
Calendar quarter
Q2 2026
Accession
0001628280-26-053883
(in thousands, except share and per share amounts)Three Months Ended June 30, 2026Three Months Ended June 30, 2025Six Months Ended June 30, 2026Six Months Ended June 30, 2025
Total other income, net1,1767862,7081,288
Net loss attributable to common stockholders$(42,109)$(52,591)$(91,231)$(104,481)
Net loss per share attributable to common stockholders, basic and diluted$(0.24)$(0.41)$(0.51)$(0.81)
Weighted-average common shares outstanding, basic and diluted177,224,892129,185,918177,160,914128,439,349
Comprehensive loss:
Net loss$(42,109)$(52,591)$(91,231)$(104,481)
Change in unrealized (loss) income on investments, net of tax(8)5(91)(11)
Comprehensive loss$(42,117)$(52,586)$(91,322)$(104,492)

Item 1. Financial Statements (unaudited)

FAQ

What is Prime Medicine's shares (diluted)?
Prime Medicine (PRME) reported shares (diluted) of 177.2M in Q2 2026.
How has Prime Medicine's shares (diluted) changed year-over-year?
Prime Medicine's shares (diluted) increased by 37.2% year-over-year, from 129.2M to 177.2M.
What is the long-term trend for Prime Medicine's shares (diluted)?
Over 3 years (2022 to 2025), Prime Medicine's shares (diluted) has grown at a 81.4% compound annual growth rate (CAGR), from 95.4M to 569.3M.
What does shares (diluted) mean?
The weighted-average shares outstanding plus all potentially dilutive shares from stock options, RSUs, convertible securities, and warrants, using the treasury stock method.

Ask your AI about Prime Medicine's shares (diluted).

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude